Nienke Z Borren1, Ashwin N Ananthakrishnan2. 1. Department of Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands. 2. Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: In this article, we provide an overview of studies examining multiomic profiling in various clinical scenarios in the management of inflammatory bowel diseases (IBDs). RECENT FINDINGS: IBD arises as a result of an interplay between genetic, environmental, microbial and immunologic perturbations. The access to high throughput technology as well as the decrease in costs associated with such studies has led to a growing wealth of literature examining the utility of single or multiomic profiles in the management of IBD. Such studies have commonly examined the genome (and less frequently the epigenome), transcriptome, metabolome, proteome and the gut microbial metagenome in the context of overall IBD status or specific clinical scenarios, including the disease progression or response to treatment. The findings have provided important insight into how each of these compartments reflect underlying disease pathophysiologic processes and, in turn, can influence stratification of patients for clinical management. SUMMARY: Multiomic profiling in IBD has the potential to advance the field of personalized precision medicine in the management of IBDs.
PURPOSE OF REVIEW: In this article, we provide an overview of studies examining multiomic profiling in various clinical scenarios in the management of inflammatory bowel diseases (IBDs). RECENT FINDINGS: IBD arises as a result of an interplay between genetic, environmental, microbial and immunologic perturbations. The access to high throughput technology as well as the decrease in costs associated with such studies has led to a growing wealth of literature examining the utility of single or multiomic profiles in the management of IBD. Such studies have commonly examined the genome (and less frequently the epigenome), transcriptome, metabolome, proteome and the gut microbial metagenome in the context of overall IBD status or specific clinical scenarios, including the disease progression or response to treatment. The findings have provided important insight into how each of these compartments reflect underlying disease pathophysiologic processes and, in turn, can influence stratification of patients for clinical management. SUMMARY: Multiomic profiling in IBD has the potential to advance the field of personalized precision medicine in the management of IBDs.
Authors: Kathleen Machiels; João Sabino; Leen Vandermosten; Marie Joossens; Ingrid Arijs; Magali de Bruyn; Venessa Eeckhaut; Gert Van Assche; Marc Ferrante; Jan Verhaegen; Kristel Van Steen; Filip Van Immerseel; Geert Huys; Kristin Verbeke; Albert Wolthuis; Anthony de Buck Van Overstraeten; Andre D'Hoore; Paul Rutgeerts; Séverine Vermeire Journal: Gut Date: 2015-09-30 Impact factor: 23.059
Authors: Subra Kugathasan; Lee A Denson; Thomas D Walters; Mi-Ok Kim; Urko M Marigorta; Melanie Schirmer; Kajari Mondal; Chunyan Liu; Anne Griffiths; Joshua D Noe; Wallace V Crandall; Scott Snapper; Shervin Rabizadeh; Joel R Rosh; Jason M Shapiro; Stephen Guthery; David R Mack; Richard Kellermayer; Michael D Kappelman; Steven Steiner; Dedrick E Moulton; David Keljo; Stanley Cohen; Maria Oliva-Hemker; Melvin B Heyman; Anthony R Otley; Susan S Baker; Jonathan S Evans; Barbara S Kirschner; Ashish S Patel; David Ziring; Bruce C Trapnell; Francisco A Sylvester; Michael C Stephens; Robert N Baldassano; James F Markowitz; Judy Cho; Ramnik J Xavier; Curtis Huttenhower; Bruce J Aronow; Greg Gibson; Jeffrey S Hyams; Marla C Dubinsky Journal: Lancet Date: 2017-03-02 Impact factor: 79.321
Authors: Peter Townsend; Qibin Zhang; Jason Shapiro; Bobbie-Jo Webb-Robertson; Lisa Bramer; Athena A Schepmoes; Karl K Weitz; Meaghan Mallette; Heather Moniz; Renee Bright; Marjorie Merrick; Samir A Shah; Bruce E Sands; Neal Leleiko Journal: Inflamm Bowel Dis Date: 2015-08 Impact factor: 5.325
Authors: Jing Wu; David M Lubman; Subra Kugathasan; Lee A Denson; Jeffrey S Hyams; Marla C Dubinsky; Anne M Griffiths; Robert N Baldassano; Joshua D Noe; Shervin Rabizadeh; Ajay S Gulati; Joel R Rosh; Wallace V Crandall; Peter D R Higgins; Ryan W Stidham Journal: Am J Gastroenterol Date: 2019-05 Impact factor: 10.864